X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (56060) 56060
Publication (4569) 4569
Book Review (1091) 1091
Newsletter (891) 891
Newspaper Article (492) 492
Book Chapter (330) 330
Magazine Article (242) 242
Book / eBook (74) 74
Conference Proceeding (56) 56
Reference (48) 48
Dissertation (40) 40
Trade Publication Article (32) 32
Transcript (11) 11
Web Resource (10) 10
Data Set (5) 5
Government Document (2) 2
Paper (2) 2
Presentation (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (35730) 35730
male (25329) 25329
index medicus (25256) 25256
animals (22995) 22995
female (19334) 19334
anti-inflammatory agents - therapeutic use (13402) 13402
inflammation (11005) 11005
anti-inflammatory agents - pharmacology (10942) 10942
adult (10615) 10615
pharmacology & pharmacy (10596) 10596
middle aged (10023) 10023
rats (9154) 9154
anti-inflammatory agents, non-steroidal - therapeutic use (8843) 8843
mice (8381) 8381
aged (6774) 6774
anti-inflammatory agents, non-steroidal - pharmacology (6617) 6617
treatment outcome (5512) 5512
anti-inflammatory agents - administration & dosage (5455) 5455
anti-inflammatory agents, non-steroidal - adverse effects (5127) 5127
nonsteroidal anti-inflammatory drugs (4943) 4943
anti-inflammatory drugs (4919) 4919
analysis (4826) 4826
immunology (4700) 4700
anti-inflammatory agents, non-steroidal - administration & dosage (4596) 4596
disease models, animal (4231) 4231
care and treatment (3818) 3818
dose-response relationship, drug (3770) 3770
research (3769) 3769
expression (3624) 3624
cytokines (3602) 3602
adolescent (3429) 3429
time factors (3341) 3341
health aspects (3332) 3332
nonsteroidal antiinflammatory drugs (3294) 3294
risk factors (3145) 3145
rats, wistar (3100) 3100
inflammation - drug therapy (3059) 3059
oxidative stress (3044) 3044
biochemistry & molecular biology (2961) 2961
rats, sprague-dawley (2936) 2936
drug therapy (2776) 2776
medicine & public health (2755) 2755
disease (2685) 2685
chemistry, medicinal (2677) 2677
gastroenterology & hepatology (2660) 2660
rheumatology (2646) 2646
inhibition (2616) 2616
double-blind method (2610) 2610
anti-inflammatory (2540) 2540
activation (2489) 2489
therapy (2469) 2469
rheumatoid-arthritis (2467) 2467
pain (2463) 2463
surgery (2451) 2451
nf-kappa-b (2382) 2382
drug therapy, combination (2373) 2373
cells (2352) 2352
cells, cultured (2351) 2351
cell biology (2332) 2332
child (2330) 2330
in-vitro (2319) 2319
neurosciences (2289) 2289
anti-inflammatory agents - adverse effects (2206) 2206
medicine, general & internal (2194) 2194
aspirin (2169) 2169
arthritis (2167) 2167
administration, oral (2159) 2159
apoptosis (2158) 2158
corticosteroids (2145) 2145
drugs (2144) 2144
rodents (2085) 2085
antioxidants (2036) 2036
anti-inflammatory agents, non-steroidal - pharmacokinetics (2029) 2029
double-blind (2010) 2010
article (1997) 1997
medicine (1954) 1954
mice, inbred c57bl (1927) 1927
prospective studies (1885) 1885
internal medicine (1874) 1874
plant extracts - pharmacology (1872) 1872
research article (1870) 1870
cancer (1847) 1847
physiological aspects (1822) 1822
young adult (1821) 1821
cytokines - metabolism (1804) 1804
macrophages (1793) 1793
medicine, research & experimental (1774) 1774
nitric oxide (1774) 1774
aged, 80 and over (1757) 1757
pharmacology/toxicology (1740) 1740
antioxidants - pharmacology (1737) 1737
asthma (1732) 1732
anti-inflammatory agents (1694) 1694
pediatrics (1679) 1679
anti-inflammatory agents - chemistry (1674) 1674
studies (1664) 1664
dermatology (1643) 1643
dosage and administration (1633) 1633
toxicology (1632) 1632
tumor necrosis factor-alpha - metabolism (1625) 1625
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (56) 56
Online Resources - Online (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
UTL at Downsview - May be requested (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (55775) 55775
German (549) 549
French (357) 357
Japanese (346) 346
Russian (317) 317
Chinese (199) 199
Spanish (147) 147
Italian (108) 108
Polish (86) 86
Dutch (26) 26
Czech (25) 25
Portuguese (25) 25
Ukrainian (25) 25
Hungarian (22) 22
Danish (21) 21
Korean (16) 16
Romanian (16) 16
Turkish (11) 11
Croatian (8) 8
Swedish (7) 7
Bulgarian (6) 6
Norwegian (6) 6
Lithuanian (5) 5
Arabic (4) 4
Hebrew (4) 4
Serbian (4) 4
Finnish (3) 3
Slovak (3) 3
Bosnian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2015, Volume 148, Issue 7, pp. 1320 - 1329.e3
Background & Aims Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn’s disease (CD) and ulcerative colitis (UC). We... 
Gastroenterology and Hepatology | Personalized Medicine | Pharmacokinetics | Therapeutic Drug Monitoring | Monoclonal Antibody | DOSE INTENSIFICATION | MAINTENANCE | THERAPY | CROHNS-DISEASE | EFFICACY | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | WITHDRAWAL | Drug Costs | Recurrence | Crohn Disease - economics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Male | Colitis, Ulcerative - immunology | Gastrointestinal Agents - economics | Antibodies, Monoclonal - blood | Drug Dosage Calculations | Anti-Inflammatory Agents - adverse effects | Infliximab | Crohn Disease - diagnosis | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Colitis, Ulcerative - drug therapy | Gastrointestinal Agents - pharmacokinetics | Anti-Inflammatory Agents - economics | Tertiary Care Centers | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Colitis, Ulcerative - blood | Crohn Disease - immunology | Remission Induction | Anti-Inflammatory Agents - blood | Algorithms | Belgium | Colitis, Ulcerative - diagnosis | Antibodies, Monoclonal - administration & dosage | Cost-Benefit Analysis | Crohn Disease - blood | Crohn Disease - drug therapy | Gastrointestinal Agents - adverse effects | Gastrointestinal Agents - blood | Colitis, Ulcerative - economics | Drug Monitoring | Antibodies, Monoclonal - economics | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Care and treatment | Continuing medical education | Consulting services | Ulcerative colitis
Journal Article
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 09/2013, Volume 33, Issue 9, pp. 2202 - 2211
OBJECTIVE—The ability of high-density lipoprotein (HDL) to remove cholesterol from atherosclerotic plaque is thought to underlie its inverse correlation with... 
high-density lipoproteins, pre-ß | cholesterol | apolipoproteins | acute coronary syndrome | inflammation | REGRESSION | LECITHINCHOLESTEROL ACYLTRANSFERASE | CELLULAR CHOLESTEROL | HUMAN ATHEROSCLEROTIC PLAQUE | high-density lipoproteins, pre-beta | INTRAVENOUS-INFUSION | TRANSPORT | PERIPHERAL VASCULAR DISEASE | MICE | HEMATOLOGY | A-I | LECITHIN | Apolipoprotein A-I - pharmacology | Lipoproteins, HDL - pharmacokinetics | Up-Regulation | Anticholesteremic Agents - blood | Lipoproteins, HDL - blood | Cholesterol - blood | Humans | Cholesterol Esters - blood | Apolipoprotein A-I - pharmacokinetics | Lipoproteins, HDL - pharmacology | Biological Transport | Female | ATP Binding Cassette Transporter 1 | Macrophages - immunology | Cytokines - blood | Cell Line | Lipoproteins, HDL - administration & dosage | Rabbits | Anti-Inflammatory Agents - pharmacology | Inflammation Mediators - blood | Particle Size | Anticholesteremic Agents - pharmacokinetics | Macrophages - metabolism | Animals | ATP-Binding Cassette Transporters - drug effects | Anticholesteremic Agents - administration & dosage | ATP-Binding Cassette Transporters - blood | Cholesterol, HDL - blood | Macrophages - drug effects | Apolipoprotein A-I - administration & dosage | Mice | Infusions, Intravenous | Anticholesteremic Agents - pharmacology | Apolipoprotein A-I - blood
Journal Article
Gastroenterology, ISSN 0016-5085, 04/2018, Volume 154, Issue 5, pp. 1343 - 1351.e1
Journal Article
Gut, ISSN 0017-5749, 09/2007, Volume 56, Issue 9, pp. 1232 - 1239
Journal Article
Atherosclerosis, ISSN 0021-9150, 2008, Volume 204, Issue 2, pp. 476 - 482
Abstract Background Risk factors of cardiovascular disease such as lipid aberrations, hypertension, abdominal adiposity and elevations in systemic... 
Cardiovascular | Cardiovascular disease | Inflammation | Hyperlipidemia | Plant sterols | Omega-3 fatty acids | C-REACTIVE PROTEIN | MYOCARDIAL-INFARCTION | SUDDEN-DEATH | OMEGA-3-FATTY-ACIDS | RISK | PHYTOSTEROLS | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | FISH-OIL | CORONARY-HEART-DISEASE | DOCOSAHEXAENOIC ACIDS | Blood Pressure | Body Composition | Hyperlipidemias - blood | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Hypolipidemic Agents - blood | Capsules | Lipids - blood | Anti-Inflammatory Agents - therapeutic use | Cardiovascular Diseases - blood | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Hyperlipidemias - diet therapy | Hyperlipidemias - physiopathology | Phytosterols - therapeutic use | Hyperlipidemias - complications | Fatty Acids, Omega-3 - administration & dosage | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Double-Blind Method | Risk Assessment | Administration, Oral | Risk Factors | Inflammation Mediators - blood | Treatment Outcome | Anti-Inflammatory Agents - blood | Phytosterols - administration & dosage | Phytosterols - blood | Hypolipidemic Agents - administration & dosage | Fatty Acids, Omega-3 - therapeutic use | Fatty Acids, Omega-3 - blood | Aged | Hypolipidemic Agents - therapeutic use | Dietary Supplements | Hypertension | Unsaturated fatty acids | Anti-inflammatory drugs | Analysis | Phytosterols | Anticholesteremic agents | Atherosclerosis
Journal Article
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 09/2014, Volume 73, Issue 9, pp. 1616 - 1625
Journal Article
by Nakase, H and Motoya, S and Matsumoto, T and Watanabe, K and Hisamatsu, T and Yoshimura, N and Ishida, T and Kato, S and Nakagawa, T and Esaki, M and Nagahori, M and Matsui, T and Naito, Y and Kanai, T and Suzuki, Y and Nojima, M and Watanabe, M and Hibi, T and Andoh, Akira and Ashida, Toshifumi and Endo, Katsuya and Endo, Yutaka and Esaki, Motohiro and Fujita, Hiroshi and Fujiya, Mikihiro and Haruma, Ken and Hibi, Toshifumi and Hiraoka, Sakiko and Hirata, Ichiro and Hisamatsu, Tadakazu and Honda, Yutaka and Iijima, Hideki and Iizuka, Bunei and Ikeya, Kentaro and Inoue, Takuya and Inoue, Shuji and Ishida, Tetsuya and Ishiguro, Yo and Ishihara, Shunji and Ito, Hiroaki and Iwakiri, Ryuichi and Kagaya, Takashi and Kanai, Takanori and Kashida, Hiroshi and Kato, Shingo and Kato, Jun and Katsurada, Takehiko and Kinjyo, Fukunori and Kobayashi, Kiyonori and Kodama, Mayumi and Kunisaki, Reiko and Kurahara, Koichi and Kurokami, Takafumi and Kyouwon, Lee and Matsuda, Koichiro and Matsueda, Kazuhiro and Matsui, Toshiyuki and Matsumoto, Takayuki and Mitsuyama, Keiichi and Mizokami, Yuji and Motoya, Satoshi and Naito, Yuji and Nakagawa, Tomoo and Nakamura, Shiro and Nakase, Hiroshi and Nojima, Masanori and Nomura, Masafumi and Ogawa, Atsuhiro and Okazaki, Kazuichi and Otsuka, Kazuaki and Sakuraba, Hirotake and Saruta, Masayuki and Sasaki, Makoto and Shirai, Takayuki and Suga, Tomoaki and Sugimura, Kazuhito and Sugiyama, Toshiro and Suzuki, Yasuo and Takeshima, Fuminao and Tamaki, Hiroyuki and Tanaka, Shinji and Tanida, Satoshi and Tominaga, Keiichi and Tomizawa, Taku and Watanabe, Kenji and Watanabe, Mamoru and Yamamoto, Shojiro and Yamashita, Masaki and Yoshida, Atsushi and Yoshimura, Naoki and DIAMOND Study Grp and DIAMOND study group
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2017, Volume 46, Issue 9, pp. 873 - 882
Summary Background Significance of monitoring adalimumab trough levels and anti‐adalimumab antibodies (AAA) for disease outcome in Crohn's disease (CD)... 
RHEUMATOID-ARTHRITIS | MAINTENANCE | INFLAMMATORY-BOWEL-DISEASE | 6-THIOGUANINE NUCLEOTIDE | IMMUNOMODULATORS | COMBINATION THERAPY | ULCERATIVE-COLITIS | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | Guanine Nucleotides - blood | Adalimumab - immunology | Thionucleotides - blood | Humans | Anti-Inflammatory Agents - immunology | Male | Treatment Outcome | Crohn Disease - immunology | Anti-Inflammatory Agents - blood | Adalimumab - therapeutic use | Mercaptopurine - therapeutic use | Adalimumab - blood | Crohn Disease - blood | Crohn Disease - drug therapy | Sensitivity and Specificity | Adalimumab - pharmacokinetics | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - pharmacokinetics | Antibodies - blood | Female | Drug Therapy, Combination | Mercaptopurine - analogs & derivatives | Measurement | Viral antibodies | Medical research | Analysis | Medicine, Experimental | Antibodies | Biopharmaceutics | Blood cells | Body weight | Erythrocytes | Diamonds | Crohn's disease | Pharmacology | Regression analysis | Thioguanine | Patients | Crohns disease | Sensitivity | Regression models | Red blood cells | Multiple regression models | Predictions | Monoclonal antibodies | Remission | Pharmacokinetics | Original | Personalised Adalimumab Pharmacokinetics
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 06/2018, Volume 84, Issue 6, pp. 1136 - 1145
Aims Tofacitinib is an oral, small molecule JAK inhibitor being investigated for ulcerative colitis (UC). In a phase 2 dose‐ranging study, tofacitinib... 
pharmacokinetics | Janus kinase | inflammatory bowel disease | INFLAMMATORY-BOWEL-DISEASE | THERAPY | CONCISE GUIDE | JANUS KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | INFLIXIMAB | Janus Kinase Inhibitors - pharmacokinetics | Pyrroles - pharmacokinetics | Pyrimidines - blood | Humans | Middle Aged | Gastrointestinal Agents - administration & dosage | Male | Colitis, Ulcerative - immunology | Piperidines - blood | Dose-Response Relationship, Drug | Janus Kinase Inhibitors - blood | Young Adult | Anti-Inflammatory Agents - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Piperidines - pharmacokinetics | Colitis, Ulcerative - drug therapy | Gastrointestinal Agents - pharmacokinetics | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Pyrimidines - administration & dosage | Treatment Outcome | Pyrroles - blood | Colitis, Ulcerative - blood | Remission Induction | Anti-Inflammatory Agents - blood | Janus Kinase Inhibitors - adverse effects | Colitis, Ulcerative - diagnosis | Janus Kinase Inhibitors - administration & dosage | Models, Biological | Piperidines - adverse effects | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Gastrointestinal Agents - adverse effects | Gastrointestinal Agents - blood | Analysis | Ulcerative colitis | Original
Journal Article
Molecular Nutrition & Food Research, ISSN 1613-4125, 04/2018, Volume 62, Issue 7, pp. e1700838 - n/a
Scope Prenylated chalcones and flavonoids from hop (Humulus lupulus L.), such as 6‐prenylnaringenin (6‐PN) and 8‐prenylnaringenin (8‐PN), are investigated for... 
peripheral blood mononuclear cells | pharmacokinetics | immune cells | human study | prenylflavonoids | FOOD SCIENCE & TECHNOLOGY | FLAVONOIDS | XANTHOHUMOL | CANCER | BEER | POTENT PHYTOESTROGEN | IN-VITRO | ISOXANTHOHUMOL | Leukocytes, Mononuclear - metabolism | Anticarcinogenic Agents - chemical synthesis | Nutritive Value | Humans | Flavanones - urine | Male | Flavonoids - adverse effects | Anticarcinogenic Agents - metabolism | Anti-Inflammatory Agents, Non-Steroidal - blood | Intestinal Absorption | Immunologic Factors - urine | Young Adult | Leukocytes, Mononuclear - immunology | Adult | Female | Anticarcinogenic Agents - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Humulus - chemistry | Flavanones - adverse effects | Flavanones - blood | Double-Blind Method | Cell Survival | Cells, Cultured | Immunologic Factors - blood | Anti-Inflammatory Agents, Non-Steroidal - analysis | Anticarcinogenic Agents - blood | Renal Elimination | Cross-Over Studies | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Flavanones - metabolism | Flavonoids - blood | Flavonoids - metabolism | Inflorescence - chemistry | Leukocytes, Mononuclear - cytology | Immunologic Factors - adverse effects | Immunologic Factors - metabolism | Flavonoids - urine | Women | Clinical trials | Health aspects | Isoflavones | Flavonoids | Men | Hops | Peripheral blood mononuclear cells | Leukocytes (mononuclear) | Bioavailability | Viability | Blood | Anticancer properties
Journal Article